Elucidating the role of tRNA epitranscriptome in Glioma pathology and development of novel therapies

• Project/Area Number: 23K27432
• Project/Area Number (Other): 23H02741 (2023)
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Multi-year Fund (2024); Single-year Grants (2023)
• Section: 一般
• Review Section: Basic Section 50010:Tumor biology-related
• Research Institution: Tohoku University
• Principal Investigator: Rashad Sherif 東北大学, 医工学研究科, 准教授 (00824088)
• Co-Investigator(Kenkyū-buntansha): 遠藤 俊毅 東北医科薬科大学, 医学部, 教授 (00535370) ; 七谷 圭 東北大学, 未来型医療創成センター, 助教 (00547333) ; 新妻 邦泰 東北大学, 医工学研究科, 教授 (10643330) ; 金森 政之 東北大学, 医学系研究科, 准教授 (60420022)
• Project Period (FY): 2023-04-01 – 2026-03-31
• Project Status: Granted (Fiscal Year 2024)
• Budget Amount: ¥18,720,000 (Direct Cost: ¥14,400,000、Indirect Cost: ¥4,320,000); Fiscal Year 2025: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000); Fiscal Year 2024: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000); Fiscal Year 2023: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
• Keywords: tRNA / Glioma / Codon bias / mRNA translation / Ferroptosis

Outline of Research at the Start

tRNA modifications were shown to impact cancer pathophysiology. Here, using high throughput mass spectrometry coupled to sequencing analysis, we will identify target tRNA modifications that can be further explored for glioma therapy.